Patients, Docs Remember Cancer Pioneer Judah Folkman

Folkman maintained close ties with EntreMed until his death. In the 2005 interview, he blamed the failure of the drug not on the company, which found the drug difficult and expensive to make, but on FDA reporting conventions. He said that the FDA measures success by tumor shrinkage, a standard appropriate only for chemotherapy agents, and that it needs to develop "language" for the kind of recovery that patients like Toner experienced.

Today, Endostatin is in development in China under the name Endostar, but it is unclear if or how it will be approved in the United States.

Toner is taking Avastin. He and his wife now have a second child.

"I don't know if my daughter is the first Avastin baby," he said. "But I can tell you that I'm looking forward to turning 40. I didn't plan on that when I was on chemo."

Page
  • 1
  • |
  • 2
  • |
  • 3
Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
 
You Might Also Like...